Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, an industry leader in artificial intelligence for drug discovery and development, today announced the appointment of Sharath Hegde, Ph.D. as its Chief ...